Items tagged with Drug-resistant TB
RESIST-TB February 2021 newsletter (post)
RESIST-TB released its February 2021 newsletter with the latest research publications on drug-resistant TB.
Call for expressions of interest: Data Curator for the Global individual patient data platform for drug-resistant TB treatment (post)
16 March 2021, Geneva | The World Health Organization Global Tuberculosis Programme has initiated a process for the establishment of Global individual patient data platform for drug-resistant tuberculosis treatment (DR-TB IPD). The DR-TB IPD is a shared platform and collaborative initiative to generate reliable evidence on drug-resistant TB treatment to inform future TB treatment guidelines and be available for researchers to analyse. The purpose of the DR-TB IPD is to facilitate pooling of individual patient data issued from researchers, local or national databases in the context of drug-resistant TB treatment and facilitate policy update, development and public health research. It will be supported by the WHO Global TB Programme and maintained by the selected Data Curator. Data Curator is the entity in charge of maintenance, curation and hosting of the DR-TB IPD.
CROI 2021: TB-related coverage (post)
2021 Conference on Retroviruses and Opportunistic Infections (CROI) was held virtually on 6-10 March 2021.
Building resilience needs to be central to treating drug-resistant TB (post)
A study published in The Lancet Global Health described distinct stages through drug-resistant TB (DR-TB) diagnosis and treatment from the point of view of patients with DR-TB and HIV in KwaZulu-Natal province, South Africa. The study emphasised that despite improvements in treatment, including shorter, all-oral regimens that include bedaquiline, DR-TB treatment remains lengthy, difficult, and life-changing for individuals.
Amid global pandemic, TB treatment innovation advances at an unprecedented pace (post)
PRETORIA (24 March 2021) — On World TB Day, as society reflects on how COVID-19 became the world’s most lethal infection in the span of a year, progress against tuberculosis (TB) can be found in the swift rollout of a short, all-oral regimen for highly drug-resistant TB infections.
Drug-resistant TB clinical trial ends enrolment early after positive initial data (post)
-- A clinical trial testing a shorter regimen for multidrug-resistant tuberculosis (MDR-TB) has stopped enrolling patients early.
-- The trial, sponsored by MSF, has stopped randomising patients because of data which has indicated the trial regimen’s superior outcomes over existing regimens.
-- We hope the data, which will be submitted for peer review, will lead to WHO to change recommendations for MDR-TB treatment.
RESIST-TB March 2021 newsletter (post)
RESIST-TB released its March 2021 newsletter with the latest research publications on drug-resistant TB.
STAND clinical trial results published (post)
March 25, 2021 – Results of TB Alliance’s Phase 3 clinical trial, known as STAND, have been published in the International Journal of Tuberculosis and Lung Disease.
Call for expressions of interest: Expert(s) for conducting data synthesis and analysis on the use of new regimens for the treatment of DR-TB (post)
The World Health Organization (WHO) Global TB Program has initiated a process to update the consolidated guidelines on the treatment of drug-resistant TB (DR-TB). The WHO Global TB Program is seeking support from independent researchers, academic institutions or other entities with relevant expertise and experience in systematic review and statistical analysis to perform the synthesis and analysis of the available data on new DR-TB treatment regimens for the guideline update.
Call for expressions of interest: Systematic reviews on hepatitis B and hepatitis C co-infection with TB and MDR/RR-TB and the effects of co-administration of MDR/RR-TB and hepatitis C treatment (post)
The World Health Organization (WHO) Global TB Program has initiated a process to conduct systematic reviews for the collection and assessment of available evidence on the prevalence of viral hepatitis B and C among patients with TB and multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) and whether the concurrent treatment of drug-resistant TB and hepatitis C is safe and increases the likelihood of treatment success and reduces unfavourable treatment outcomes.
Page 68 of 117 · Total posts: 0
←First 67 68 69 Last→